CA-BEHAVIOSEC
31.5.2019 15:02:03 CEST | Business Wire | Press release
BehavioSec, the first vendor to pioneer behavioral biometrics, is attending Money20/20 Europe on June 3-5, 2019 in Amsterdam, Netherlands at the Amsterdam RAI. Money20/20 focuses on the mission of creating a simpler, fairer, faster and more inclusive financial system for individuals, businesses and society as a whole, bringing together more than 350 speakers to deliver the next frontier of Financial Services. BehavioSec CEO Neil Costigan will join the panel discussion, “The Changing Nature of Attacks and Attackers,” where he will discuss cybersecurity and risk management in an age where online commerce and trust are threatened by cybercrime threats continually bypassing traditional password authentication and anti-fraud measures.
Money20/20 attendees can visit BehavioSec at booth H92 throughout the event. BehavioSec will meet with customers and industry partners, brief media and analysts and present demos of the company’s Behavioral Biometrics Software Platform . Already in use with some of the biggest global brands in FinTech and financial services, BehavioSec’s software provides continuous online authentication of account holders by analyzing their unique physical behaviors, like typing patterns, cursor movements and touchscreen inputs.
“Traditional, one-time authentication measures like thumbprints and passwords can no longer protect and enable digital transformation in the financial services sector,” said Costigan. “With today’s constantly evolving attacks bypassing even once reliable multi-factor authentication methods, financial service organizations must find new ways to prevent fraud and cyber attacks without slowing down usability and functionality. Presenting at Money20/20 gives us the opportunity to show the success of behavioral biometrics in combating account takeover fraud in this new threat landscape.”
Join BehavioSec’s Neil Costigan at the following session:
|
What: |
The Changing Nature of Attacks and Attackers |
|
|
Who: |
Neil Costigan, CEO, BehavioSec (Speaker) | |
| Dr. Yinglian Xie, Co-Founder and CEO, DataVisor (Speaker) | ||
| Max Laemmle, Founder and CEO, Fraugster Limited (Speaker) | ||
| Andrew Jamieson, Technology & Security Director, UL (Moderator) | ||
|
When: |
Wednesday, June 5, 2019 from 14:10 p.m. to 14:50 p.m. CEST | |
|
Where: |
Industry Transmutation Stage at RAI Amsterdam, Amsterdam, Netherlands |
As CEO of BehavioSec, Costigan leads the company’s work delivering innovative behavioral biometric technology protecting consumer transactions, payments and financial firms from fraud and theft. He has more than 25 years’ of entrepreneurial and technical leadership experience in venture-backed startups, and global technology corporations spanning the U.S., and EU. A cryptographer by training, his career expanded to include software development, executive leadership and entrepreneurship. He holds an extensive portfolio of patents and serves as Principal Investigator for BehavioSec’s U.S. DOD DARPA projects.
Prior to BehavioSec, Costigan was VP for R&D at Smart Card manufacturer Gemplus (now Gemalto) and Co-founder/CTO at PKI specialists Celo Communications (Celo). Neil holds a PhD (2009) for his thesis on Elliptic Curve Cryptography on Modern Processor Architectures and has developed a number of commercial security applications. He frequently presents and presents on innovation, cryptography and network security.
Follow BehavioSec for more details and the latest in behavioral biometrics technology:
About BehavioSec
BehavioSec is the first vendor to pioneer behavioral biometrics. The company’s Behavioral Biometrics Platform is widely deployed across Global 2000 companies for its proven ability to dramatically reduce account fraud and data theft. Founded in 2008 out of groundbreaking academic research, BehavioSec technology allows companies to continuously verify digital identities with superior precision, in real-time. Strengthened with the leadership of serial entrepreneurs and experienced industry professionals, the BehavioSec team now spans the world, providing security while preserving a rich digital experience throughout web and mobile apps. BehavioSec is the only enterprise-grade vendor used in global deployments with some of the largest companies, reducing manual review whilst safeguarding millions of users and billions of transactions. BehavioSec investors include Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures and Octopus Ventures. BehavioSec is headquartered in San Francisco, CA and has global operations throughout Europe and Asia Pac. For more information, visit www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190531005032/en/
Contact:
Media Contact: Savannah Young +1 (703) 877-8111 pr@behaviosec.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom